Pharmacy Prior Authorization Criteria

Zenbexus (iberdomide)

Indications for Prior Authorization

Zenbexus (iberdomide)

• For diagnosis of Multiple Myeloma
  Indicated in combination with daratumumab and hyaluronidase-fihj and dexamethasone, for the treatment of adult patients with multiple myeloma who have received at least 1 prior line of therapy including a proteasome inhibitor and an immunomodulatory agent. This indication is approved under accelerated approval based on minimal residual disease (MRD)-negative complete response (CR) at any time. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s).

Criteria

Zenbexus

Prior Authorization (Initial Authorization)

Length of Approval: 12 Month(s)

• Diagnosis of multiple myeloma
AND
• Disease is relapsed or refractory
AND
• Patient has received a prior line of therapy including both of the following:
• One proteasome inhibitor (e.g., bortezomib)
• One immunomodulatory agent (e.g., pomalidomide, lenalidomide)
AND
• Used in combination with both of the following:
• Darzalex (daratumumab) or Darzalex Faspro (daratumumab and hyaluronidase-fihj)
• Dexamethasone

Zenbexus

Prior Authorization (Reauthorization)

Length of Approval: 12 Month(s)

• Patient does not show evidence of progressive disease while on therapy

P & T Revisions

2026-10-12

References

1. Zenbexus Prescribing Information. Bristol-Myers Squibb Company. Princeton, NJ. August 2026.
2. National Comprehensive Cancer Network (NCCN) Drugs and Biologics Compendium. Available by subscription at: www.nccn.org. Accessed August 9, 2026.

---

Revision History

• 2026-10-12: New Program

---